9/5/2023

Dexamethasone Sodium Phosphate Injection

Products Affected - Description

- Dexamethasone Sodium Phosphate injection, Eugia US, 10 mg/mL, 1 mL preservative-free vial, 25 count, NDC 55150-0304-25
- Dexamethasone Sodium Phosphate injection, Hikma, 4 mg/mL, 1 mL vial, 25 count, NDC 00641-6145-25
- Dexamethasone Sodium Phosphate injection, Hikma, 4 mg/mL, 5 mL vial, 25 count, NDC 00641-6146-25

Reason for the Shortage

- American Regent is not marketing dexamethasone sodium phosphate injection at this time.
- Eugia has dexamethasone injection on shortage due to increased demand.
- Fresenius Kabi has dexamethasone sodium phosphate on shortage due to increased demand.
- Viatris has dexamethasone injection available.
- Hikma has dexamethasone injection on shortage due to increased demand.
- Somerset Therapeutics had 10 mg/mL 1 mL and 10 mL vials on shortage due to increased demand.

Available Products

- Dexamethasone Sodium Phosphate injection, Eugia US, 10 mg/mL, 10 mL vial, 10 count, NDC 55150-0305-10
- Dexamethasone Sodium Phosphate injection, Eugia US, 4 mg/mL, 30 mL vial, 25 count, NDC 55150-0239-30
- Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 10 mg/mL, 1 mL prefilled syringe, 24 count, NDC 76045-0109-10
- Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 10 mg/mL, 1 mL preservative-free single dose vial, 25 count, NDC 63323-0506-01
- Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 10 mg/mL, 10 mL multiple dose vial, 10 count, NDC 63323-0516-10
- Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 4 mg/mL, 1 mL prefilled syringe, 24 count, NDC 76045-0106-10
- Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 4 mg/mL, 1 mL single dose vial, 25 count, NDC 63323-0165-01
- Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 4 mg/mL, 30 mL multiple dose vial, 1 count, NDC 63323-0165-30
- Dexamethasone Sodium Phosphate injection, Fresenius Kabi, 4 mg/mL, 5 mL multiple dose vial, 25 count, NDC 63323-0165-05
- Dexamethasone Sodium Phosphate injection, Hikma, 10 mg/mL, 1 mL vial, 25 count, NDC 00641-0367-25
- Dexamethasone Sodium Phosphate injection, Mylan Institutional (Viatris), 10 mg/mL, 10 mL vial, 10 count, NDC 67457-0420-10
- Dexamethasone Sodium Phosphate injection, Mylan Institutional (Viatris), 4 mg/mL, 1 mL vial, 25 count, NDC 67457-0423-12
- Dexamethasone Sodium Phosphate injection, Mylan Institutional (Viatris), 4 mg/mL, 30 mL vial, 25 count, NDC 67457-0421-30
- Dexamethasone Sodium Phosphate injection, Mylan Institutional (Viatris), 4 mg/mL, 5 mL vial, 25 count, NDC 67457-0422-54
- Dexamethasone Sodium Phosphate injection, Somerset Therapeutics LLC, 10 mg/mL, 1 mL preservative-free vial, 25 count, NDC 70069-0021-25
- Dexamethasone Sodium Phosphate injection, Somerset Therapeutics LLC, 10 mg/mL, 10 mL multiple dose vial, 10 count, NDC 70069-0025-10

Estimated Resupply Dates

- Eugia has dexamethasone sodium phosphate 10 mg/mL 1 mL preservative-free vials on intermittent back order and the company is releasing product as it becomes available.
- Hikma has dexamethasone sodium phosphate 4 mg/mL 1 mL vials on allocation. The 4 mg/mL 5 mL vials are on back order and the company cannot estimate a release date.

Updated

Updated September 5, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 18, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.